About Us

Syed Kazmi is President and Chief Executive officer of Jubilant Therapeutics Inc., a subsidiary of Jubilant Pharmova Limited. Jubilant Therapeutics is a US-based innovative biopharmaceutical company developing breakthrough therapies for treating unmet medical needs in serious diseases such as cancer.

Previously, Syed worked as the Vice President and Global Head of Oncology Business Development & Licensing at Novartis, leading all BD&L efforts for Novartis Oncology including Search & Evaluation, Transactions, Due Diligence and Alliance Management. Prior to Novartis, Syed worked as the Executive Director of Business Development at Amgen, responsible for corporate mergers and acquisitions, global licensing and strategic collaborations; he also served as the Head of International Business Development.

Before joining Amgen in 2012, Syed served as Vice President and Head, Business Development & Strategic Planning, at Ligand Pharmaceuticals. Syed also worked for Johnson & Johnson as Principal Scientist in the R&D organization. Syed has a Ph.D. in Life Sciences (Biochemistry) and an executive MBA.

Melda Dolan is Chief Medical Officer of Jubilant Therapeutics Inc. (JTx), a subsidiary of Jubilant Pharmova Limited, bringing over 30 years of experience in medicine, cardiology, research, imaging and innovation in academic and pharmaceutical medicine to global healthcare.

Previously, Melda was Global Medical and Regulatory Affairs Executive Senior Director at Bracco Diagnostics and Research Professor at Saint Louis University Hospital Internal Medicine Cardiology. She served as a key opinion leader in healthcare globally.

Shyam is CFO at Jubilant Therapeutics Inc. that he helped carve-out from the parent company Jubilant Pharmova Limited and set up as a standalone US-based biotech venture in 2019. Shyam is also involved in other initiatives at Jubilant such as corporate venture investing, digital and innovation.

Earlier he managed the strategy office at a leading India-based conglomerate where he helped scale a new business and managed a successful M&A exit valued at over a billion dollars. Before Shyam's industry stints, he spent most of his career as a management consultant at PwC – advising startups and leading global companies in strategy. Shyam has spoken at various conferences and is an active participant in the World Economic Forum community in addition to authoring over fifty thought leadership publications.

He is a graduate of the London School of Economics and State University of New York.